老年人同时接种23价肺炎球菌多糖疫苗与流感疫苗的安全性
本研究利用韩国疾病管理厅预防接种登记与国家健康保险服务理赔数据链接的回顾性队列,纳入2016年1月1日至2020年12月31日至少接种一次PPSV-23的65岁以上老年人,比较同日同时接种与序贯接种流感疫苗的16项预设不良事件。经1:4倾向评分匹配和条件Poisson回归调整混杂后,同时接种组过敏反应、神经炎和肺炎风险显著低于序贯组,麻痹风险显著高于序贯组。结论认为同时接种与多数预设不良事件风险升高无关,支持其安全性。
要点
- 同时接种组过敏反应风险显著低于序贯组(aIRR 0.71,95%CI 0.58-0.87)。
- 同时接种组神经炎风险显著低于序贯组(aIRR 0.72,95%CI 0.57-0.91)。
- 同时接种组肺炎风险显著低于序贯组(aIRR 0.85,95%CI 0.80-0.90),麻痹风险显著高于序贯组(aIRR 1.63,95%CI 1.05-2.52)。
核心结论
- 老年人同时接种PPSV-23与流感疫苗与多数预设不良事件风险升高无关,研究支持其安全性。
研究设计与样本
- 回顾性队列研究,链接韩国疾病管理厅预防接种登记与国家健康保险服务理赔数据。
- 纳入2016年1月1日至2020年12月31日至少接种一次PPSV-23的65岁以上老年人。
- 同时接种定义为同日接种PPSV-23与流感疫苗;序贯接种定义为PPSV-23注射日前30至365天内接种流感疫苗。
- 采用1:4倾向评分匹配,以条件Poisson回归估计调整后发病率比(aIRR)及95%CI。
- 评估16项预设不良事件。
主要发现
- 2016年1月1日至2020年12月31日至少接种一次PPSV-23的老年人共2,885,144例,同时接种组87,899例,序贯接种组1,200,091例。
- 同时接种组过敏反应风险显著低于序贯组(aIRR 0.71,95%CI 0.58-0.87)。
- 同时接种组神经炎风险显著低于序贯组(aIRR 0.72,95%CI 0.57-0.91)。
- 同时接种组肺炎风险显著低于序贯组(aIRR 0.85,95%CI 0.80-0.90)。
- 同时接种组麻痹风险显著高于序贯组(aIRR 1.63,95%CI 1.05-2.52)。
关键数值与推荐
- 同时接种组 vs 序贯接种组:过敏反应aIRR 0.71(95%CI 0.58-0.87),同时接种组风险显著降低。
- 同时接种组 vs 序贯接种组:神经炎aIRR 0.72(95%CI 0.57-0.91),同时接种组风险显著降低。
- 同时接种组 vs 序贯接种组:肺炎aIRR 0.85(95%CI 0.80-0.90),同时接种组风险显著降低。
- 同时接种组 vs 序贯接种组:麻痹aIRR 1.63(95%CI 1.05-2.52),同时接种组风险显著升高。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current recommendation for the elderly is to receive both a single dose 23-valent pneumococcal polysaccharide vaccine (PPSV-23) and an annual inactivated influenza vaccine. There is a lack of post-marketing safety studies on concomitant vaccination using real-world data. We aimed to evaluate the safety of administering PPSV-23 and influenza vaccine concomitantly versus sequentially. METHODS: We performed a retrospective cohort study using a linked database that combines vaccination registry from the Korea Disease Control and Prevention Agency and claims data from the National Health Insurance Service. The study population included all those aged over 65 who received PPSV-23 at least once from Jan 1, 2016, to Dec 31, 2020. This study evaluated the 16 prespecified events of interest. Concomitant vaccination was defined as receiving both PPSV-23 and influenza vaccine on the same day. For sequential vaccination, we defined it as receiving influenza vaccination during the period from 30 to 365 days prior to the date of PPSV-23 injection. We performed 1:4 propensity score matching and estimated adjusted incidence rate ratio (aIRR) with a 95 % confidence interval (CI) using conditional Poisson regression. RESULTS: Of the 2,885,144 elderly patients who received PPSV-23 vaccination at least once from Jan 1, 2016, to Dec 31, 2020, a total 87,899 were included in the concomitant vaccination group and 1,200,091 were included in the sequential vaccination group. After adjusting for confounders, the concomitant group exhibited a significantly lower risk of allergic reactions (aIRR: 0.71, 95 % CI: 0.58-0.87), neuritis (aIRR: 0.72, 95 % CI: 0.57-0.91), and pneumonia (aIRR: 0.85, 95 % CI: 0.80-0.90), while demonstrating significantly higher risks of paralysis (aIRR: 1.63, 95 % CI: 1.05-2.52) compared to the sequential group. CONCLUSIONS: Concomitant administration of PPSV-23 and influenza vaccine in the elderly was not associated with a higher risk of most prespecified adverse events (AEs) compared to sequential vaccination. This study supports the safety of concomitant administration of PPSV-23 and influenza vaccine.
引用
- Won H, Kim JA, Jeong NY, et al. Safety of concomitant administration of 23-valent polysaccharide pneumococcal vaccine and influenza vaccine among the elderly. Vaccine. 2024. PMID: 38641496. doi:10.1016/j.vaccine.2024.03.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。